Date Title
May 21, 2018
Realm Therapeutics Presents Data Highlighting its Proprietary Immunomodulatory Technology's Potential in Acne and Psoriasis at IID 2018

MALVERN, Pa. , May 21, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company presented a poster at the 2018 International Investigative Dermatology

May 2, 2018
Realm Therapeutics Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares
MALVERN, Pa. , May 2, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM) (the Company), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces it has confidentially submitted a registration statement to the United States
April 26, 2018
Realm Therapeutics plc ("Realm Therapeutics", "Realm", or the "Company") Notice of Full Year 2017 Results
MALVERN, Pa. , April 26, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company expects to release its results for the year ended December 31, 2017 on
Displaying 31 - 33 of 33

Search Investor Relations